- Home
- FEBO vs PHGE Comparison
FEBO vs PHGE Comparison
Compare FEBO & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEBO
- PHGE
- Stock Information
- Founded
- FEBO 1993
- PHGE 2015
- Country
- FEBO Hong Kong
- PHGE Israel
- Employees
- FEBO N/A
- PHGE N/A
- Industry
- FEBO
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- FEBO
- PHGE Health Care
- Exchange
- FEBO Nasdaq
- PHGE Nasdaq
- Market Cap
- FEBO 12.7M
- PHGE 13.3M
- IPO Year
- FEBO 2023
- PHGE N/A
- Fundamental
- Price
- FEBO $1.22
- PHGE $0.61
- Analyst Decision
- FEBO
- PHGE Strong Buy
- Analyst Count
- FEBO 0
- PHGE 2
- Target Price
- FEBO N/A
- PHGE $23.00
- AVG Volume (30 Days)
- FEBO 11.8K
- PHGE 191.5K
- Earning Date
- FEBO 05-02-2025
- PHGE 05-19-2025
- Dividend Yield
- FEBO N/A
- PHGE N/A
- EPS Growth
- FEBO N/A
- PHGE N/A
- EPS
- FEBO N/A
- PHGE N/A
- Revenue
- FEBO $16,319,897.00
- PHGE N/A
- Revenue This Year
- FEBO N/A
- PHGE N/A
- Revenue Next Year
- FEBO N/A
- PHGE N/A
- P/E Ratio
- FEBO N/A
- PHGE N/A
- Revenue Growth
- FEBO 9.01
- PHGE N/A
- 52 Week Low
- FEBO $0.93
- PHGE $0.48
- 52 Week High
- FEBO $17.68
- PHGE $4.99
- Technical
- Relative Strength Index (RSI)
- FEBO 52.81
- PHGE 54.05
- Support Level
- FEBO $1.04
- PHGE $0.52
- Resistance Level
- FEBO $1.22
- PHGE $0.57
- Average True Range (ATR)
- FEBO 0.12
- PHGE 0.05
- MACD
- FEBO 0.01
- PHGE 0.01
- Stochastic Oscillator
- FEBO 62.07
- PHGE 80.18
About FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.